Announcement • May 08
Inspire Veterinary Partners, Inc. Files Form 15 Inspire Veterinary Partners, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock, par value $0.0001 per share under the Securities Exchange Act of 1934, as amended. Announcement • Apr 01
Inspire Veterinary Partners, Inc. announced delayed annual 10-K filing On 03/31/2026, Inspire Veterinary Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Jan 22
Inspire Veterinary Partners, Inc.(OTCPK:IVPR) dropped from NASDAQ Composite Index Inspire Veterinary Partners, Inc dropped from the NASDAQ Composite Index.. Announcement • Nov 25
Inspire Veterinary Partners, Inc. Receives Notice of Nasdaq Delisting Due to Non-Compliance with Bid Price Rule As reported previously on the Current Report on Form 8-K filed by Inspire Veterinary Partners, Inc. (the “Company”) on November 17, 2025, the Company received a notice letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share, for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). The Notice stated that the Company’s securities would be suspended from trading on The Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE would be filed with the U.S. Securities and Exchange Commission, which would remove the Company’s securities from listing and registration on Nasdaq, unless the Company requested an appeal of such determination to Nasdaq’s Hearings Panel (the “Panel”) by November 20, 2025. The Company requested a hearing before the prescribed date, which request will stay any further suspension or delisting action by Nasdaq pending the ultimate conclusion of the hearing process. On November 21, 2025, the Company was informed that the hearing is scheduled for January 13, 2026. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq. Announcement • Nov 18
Inspire Veterinary Partners, Inc. Receives Notice of Non-Compliance from Nasdaq On November 13, 2025, Inspire Veterinary Partners, Inc. (the “Company”) received a notice letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share, for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2). Further, the Notice stated that, pursuant to Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period specified in Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period and has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Notice stated that the Company’s securities will be suspended from trading on The Nasdaq Capital Market at the opening of business on November 24, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq, unless the Company requests an appeal of such determination to Nasdaq’s Hearings Panel (the “Panel”) by November 20, 2025. The Company intends to request a hearing before the prescribed date, which request will stay any further suspension or delisting action by Nasdaq pending the ultimate conclusion of the hearing process. There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq. Announcement • Oct 27
Inspire Veterinary Partners, Inc., Annual General Meeting, Dec 10, 2025 Inspire Veterinary Partners, Inc., Annual General Meeting, Dec 10, 2025. New Risk • Aug 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Market cap is less than US$10m (US$7.56m market cap). Reported Earnings • Aug 14
Second quarter 2025 earnings released: US$0.50 loss per share (vs US$17.59 loss in 2Q 2024) Second quarter 2025 results: US$0.50 loss per share (improved from US$17.59 loss in 2Q 2024). Revenue: US$4.28m (down 2.4% from 2Q 2024). Net loss: US$3.03m (loss narrowed 11% from 2Q 2024). New Risk • Jul 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$3.38m market cap). New Risk • May 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Earnings have declined by 54% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 65x increase in shares outstanding). Market cap is less than US$10m (US$7.42m market cap). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). Reported Earnings • May 16
First quarter 2025 earnings released: US$0.43 loss per share (vs US$224 loss in 1Q 2024) First quarter 2025 results: US$0.43 loss per share (improved from US$224 loss in 1Q 2024). Revenue: US$3.64m (down 25% from 1Q 2024). Net loss: US$2.42m (loss narrowed 34% from 1Q 2024). Reported Earnings • Apr 01
Full year 2024 earnings released Full year 2024 results: US$2.61 loss per share. Revenue: US$16.6m (flat on FY 2023). Net loss: US$14.5m (loss narrowed 3.8% from FY 2023). Board Change • Mar 11
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Director Phillip Balatsos was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Dec 18
Inspire Veterinary Partners Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement of Nasdaq Listing Rule 5550(a)(2) On December 12, 2024, Inspire Veterinary Partners, Inc. (the ‘Company’) received a letter from the Listing Qualifications Staff (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that it has demonstrated compliance with the minimum equity requirement in Listing Rule 5550(b)(1) as required by the Hearing Panel (‘Panel’). Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year, until December 12, 2025. Additionally, the letter stated that upon further review of the terms and conditions of the ‘best efforts’ offering closed by the Company on July 12, 2024, the Staff determined that the offering was not a ‘public offering’ for the purposes of Nasdaq’s shareholder approval rules and accordingly, the Company was required, but failed, to obtain shareholder approval under the Listing Rule 5635(d) prior to issuing the securities in the offering. The Company obtained post-execution shareholder ratification of the offering and the Panel determined a Public Reprimand Letter is an appropriate resolution to this matter. On December 16, 2024, the Company received a letter from the Staff notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share, for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Requirement’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a grace period of 180 days, or until June 16, 2025, to regain compliance with the Minimum Bid Price Requirement. Reported Earnings • Nov 15
Third quarter 2024 earnings released: US$0.19 loss per share (vs US$125 loss in 3Q 2023) Third quarter 2024 results: US$0.19 loss per share (improved from US$125 loss in 3Q 2023). Revenue: US$4.05m (down 1.7% from 3Q 2023). Net loss: US$3.49m (loss narrowed 56% from 3Q 2023). Announcement • Oct 23
Inspire Veterinary Partners, Inc. has filed a Follow-on Equity Offering in the amount of $2.5 million. Inspire Veterinary Partners, Inc. has filed a Follow-on Equity Offering in the amount of $2.5 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 1,800,000
Price\Range: $0.25
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 8,200,000
Price\Range: $0.25
Transaction Features: Registered Direct Offering Announcement • Oct 01
Inspire Veterinary Partners Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5635(d) On September 24, 2024, Inspire Veterinary Partners, Inc. (the Company") received a staff determination letter from the Listing Qualifications Staff (the Staff") of The Nasdaq Stock Market (Nasdaq") notifying the Company that, based on its review of the Company's securities, the Staff determined that the Company failed to comply with Nasdaq's shareholder approval requirements set in Listing Rule 5635(d). The Staff stated that the Company's best efforts" public offering, which closed on July 15, 2024, did not qualify as a public offering for the purposes of Nasdaq's shareholder approval rules. As such, Listing Rule 5635(d),which requires prior shareholder approval for transactions other than public offerings involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Price was not met. Accordingly, this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The Company will present its views with respect to this additional deficiency to the Nasdaq Hearings Panel (the Panel") in writing no later than October 1, 2024. The Company's securities will not be suspended or delisted while the Panel makes its determination regarding the Company's continued listing on Nasdaq. New Risk • Aug 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.75m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.8m free cash flow). Share price has been highly volatile over the past 3 months (61% average weekly change). Negative equity (-US$3.1m). Earnings have declined by 79% per year over the past 5 years. Market cap is less than US$10m (US$9.75m market cap). Minor Risk Significant insider selling over the past 3 months (US$498k sold). Reported Earnings • Aug 15
Second quarter 2024 earnings released: US$0.70 loss per share (vs US$23.30 loss in 2Q 2023) Second quarter 2024 results: US$0.70 loss per share. Revenue: US$4.39m (down 2.2% from 2Q 2023). Net loss: US$3.39m (loss widened 176% from 2Q 2023). Announcement • Aug 14
Inspire Veterinary Partners, Inc., Annual General Meeting, Oct 09, 2024 Inspire Veterinary Partners, Inc., Annual General Meeting, Oct 09, 2024. Location: 780 lynnhaven parkway, suite 400, virginia beach, va 23452, United States Announcement • Jul 10
Inspire Veterinary Partners, Inc. has completed a Composite Units Offering in the amount of $6 million. Inspire Veterinary Partners, Inc. has completed a Composite Units Offering in the amount of $6 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 6,000,000
Price\Range: $1
Discount Per Security: $0.08 Board Change • Jul 01
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Anne Murphy was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • May 08
Inspire Veterinary Partners to Implement Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement Inspire Veterinary Partners, Inc. announced that it will effect a 1-for-100 reverse stock split of its authorized and issued and outstanding shares of Class A common stock, par value $0.0001 per share. The Reverse Stock Split will become effective at 12:01am, Eastern Time, on May 8, 2024. At such time, each 100 shares of issued and outstanding Common Stock will automatically be reclassified into one new share of Common Stock. Inspire's Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "IVP" and will begin trading on a split-adjusted basis when the market opens on May 8, 2024. The new CUSIP number for the Common Stock following the Reverse Stock Split will be 45784E 205. The Reverse Stock Split is primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement in order to maintain its listing on Nasdaq. There is no guarantee the Company will meet the minimum bid price requirement. Announcement • Apr 16
Inspire Veterinary Partners Receives Staff Determination from The Nasdaq Stock Market Due to No Longer Complies with Nasdaq’s Listing Rule On April 11, 2024, Inspire Veterinary Partners, Inc. (the ‘Company’) received a staff determination from The Nasdaq Stock Market (‘Nasdaq’) notifying the Company that, based on the Company’s stockholders’ equity of ($788,259) as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission, the Company does not meet the alternatives of market value of listed securities or net income from continuing operations. As such, the Company no longer complies with Nasdaq’s Listing Rule (the ‘Rule’). Accordingly, this matter serves as an additional basis for delisting the Company’s securities from Nasdaq. The Company currently has a hearing date with the Nasdaq Hearings Panel (the ‘Panel’) scheduled for May 14, 2024. The Company will present its plan of compliance with respect to this additional deficiency at its Panel hearing. The Company’s securities will not be suspended or delisted while the Panel makes its determination regarding the Company’s continued listing on Nasdaq. Announcement • Apr 02
Inspire Veterinary Partners, Inc. announced delayed annual 10-K filing On 04/01/2024, Inspire Veterinary Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Announcement • Mar 13
Inspire Veterinary Partners Receives Staff Determination from The Nasdaq Stock Market to Delist its Securities from the Nasdaq Capital Market On March 8, 2024, Inspire Veterinary Partners, Inc. (the ‘Company’) received a staff determination from The Nasdaq Stock Market (‘Nasdaq’) to delist the Company’s securities from the Nasdaq Capital Market (the ‘Staff Determination’). The Staff Determination was issued because, as of March 7, 2024, the Company’s securities had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the ‘Low Priced Stocks Rule’). The Company may appeal the Staff Determination, however, to a Hearings Panel (the ‘Panel’) by filing a hearing request with Nasdaq on or before March 15, 2024 pursuant to the procedures set in the Nasdaq Listing Rule 5800 Series. Hearings are typically scheduled to occur approximately 30-45 days after the date of the hearing request. A hearing request will stay the delisting of the Company’s securities pending the Panel’s decision. Previously, on November 27, 2023, the Company received a deficiency letter from the Listing Qualifications Department of Nasdaq indicating that the Company’s common stock is subject to potential delisting from the Nasdaq because, for a period of 30 consecutive business days, the bid price of the Company’s common stock had closed below the required minimum of $1.00 per share under Nasdaq Marketplace Rule 5550(a)(2) (the ‘Bid Price Rule’). The Company intends to appeal the Staff Determination under the Low Priced Stock Rule and will file a hearing request with Nasdaq by March 15, 2024. Pending the hearing before the Panel, the Company’s securities will continue to be listed on the Nasdaq Capital Market. In the immediate future, the Company intends to implement an appropriate reverse split of its Class A Common Stock in order to regain compliance with both the Low Priced Stocks Rule and the Bid Price Rule. There can be no assurance, however, that the Company will be able to regain compliance with the Bid Price Rule and the Low Priced Stocks Rule or that it will otherwise be in compliance with other Nasdaq listing rules. Additional information will be disclosed regarding the planned reverse split in the near future. Announcement • Feb 09
Inspire Veterinary Partners, Inc. has filed a Follow-on Equity Offering. Inspire Veterinary Partners, Inc. has filed a Follow-on Equity Offering.
Security Name: Class A Common Shares
Security Type: Common Stock
Securities Offered: 47,058,823
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 47,058,823
Transaction Features: Registered Direct Offering Announcement • Jan 05
Inspire Veterinary Partners, Inc. has filed a Follow-on Equity Offering in the amount of $5 million. Inspire Veterinary Partners, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.
Security Name: Class A Common Stock
Security Type: Common Stock Announcement • Dec 03
Inspire Veterinary Partners Receives Non-Compliance Notice From Nasdaq On November 27, 2023, Inspire Veterinary Partners, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company’s common stock is subject to potential delisting from the Nasdaq because for a period of 30 consecutive business days, the bid price of the Company’s common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Nasdaq Marketplace Rule 5550(a)(2) (the “Bid Price Rule”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol “IVP” at this time. The Nasdaq notice indicated that, in accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company will be provided 180 calendar days, or until May 28, 2024, to regain compliance. If, at any time before May 28, 2024, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq staff will provide written notification that it has achieved compliance with the Bid Price Rule. If the Company fails to regain compliance with the Bid Price Rule before May 28, 2024 but meets all of the other applicable standards for initial listing on The Nasdaq Capital Market with the exception of the minimum bid price, then the Company may be eligible to have an additional 180 calendar days, or until November 24, 2024, to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by the end of the compliance period (or the second compliance period, if applicable), the Company’s common stock will become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing rules permit the Company to appeal a delisting determination by Nasdaq to a hearings panel. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule or will otherwise be in compliance with other Nasdaq listing rules. Reported Earnings • Nov 16
Third quarter 2023 earnings released: US$1.23 loss per share (vs US$0.32 loss in 3Q 2022) Third quarter 2023 results: US$1.23 loss per share (further deteriorated from US$0.32 loss in 3Q 2022). Revenue: US$4.12m (up 41% from 3Q 2022). Net loss: US$7.88m (loss widened 377% from 3Q 2022). Announcement • Nov 10
Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) completed the acquisition of Substantially All of the Assets of Valley Veterinary Service, Inc. Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) entered into a non-binding letter of intent to acquire Substantially All of the Assets of Valley Veterinary Service, Inc. on September 21, 2023. Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) entered into a definitive agreement to acquire Substantially All of the Assets of Valley Veterinary Service, Inc. for $2.8 million on October 27, 2023. The aggregate purchase consideration for the Valley Veterinary Service animal hospital is $1,400,000 plus the assumed liabilities described below, consisting of $1,000,000 to be paid in cash at the closing of the acquisition plus a number of restricted shares of the Company’s Class A common stock (the “Class A Common Stock”) equal to the quotient obtained by dividing $400,000 by the official closing price of one share of Class A Common Stock as reported by the Nasdaq Capital Market on the trading date immediately prior to the closing. At Closing, a portion of the Purchase Price equal to Two Hundred Thousand and No/100 Dollars ($200,000.00) (the “ Holdback Amount ”) shall be deposited into an escrow account (the “ Holdback Escrow Account ”) in the name of IVP with a financial institution selected by IVP in its discretion. $80,000.00 of the Holdback Amount will be released day before the first anniversary of the Effective Date. $120,000.00 of the Holdback Amount will be released day before the second anniversary of the Effective Date. Inspire's due diligence review of the target acquisition has already commenced, and upon satisfactory completion, the Company intends to proceed towards executing a definitive acquisition agreement and closing the transaction as soon as all closing conditions are met. The letter of intent is non-binding and subject to additional diligence and other factors. The proposed acquisition is subject to customary closing conditions and is currently expected to be completed as early as the third quarter of 2023. H. Derek Hall of Rose Grasch Camenisch Mains PLLC acted as legal advisor for Inspire Veterinary Partners, Inc.
Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) completed the acquisition of Substantially All of the Assets of Valley Veterinary Service, Inc. on November 8, 2023. The aggregate purchase consideration for the Valley Veterinary Services animal hospital practice was $1,400,000 plus the assumed liabilities described below, consisting of $1,000,000 to be paid in cash at the closing of the acquisition plus 408,163 restricted shares of the Company’s Class A common stock (the “Class A Common Stock”), which was equal to the quotient obtained by dividing $400,000 by the official closing price of one share of Class A Common Stock as reported by the Nasdaq Capital Market on the trading date immediately prior to the closing. New Risk • Oct 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.94m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$2.3m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Negative equity (-US$7.9m). Market cap is less than US$10m (US$9.94m market cap). Announcement • Sep 23
Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) entered into a non-binding letter of intent to acquire a 100% ownership interest in one animal hospital located in Pennsylvania. Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) entered into a non-binding letter of intent to acquire a 100% ownership interest in one animal hospital located in Pennsylvania on September 21, 2023. Inspire's due diligence review of the target acquisition has already commenced, and upon satisfactory completion, the Company intends to proceed towards executing a definitive acquisition agreement and closing the transaction as soon as all closing conditions are met. The letter of intent is non-binding and subject to additional diligence and other factors. The proposed acquisition is subject to customary closing conditions and is currently expected to be completed as early as the third quarter of 2023. Announcement • Sep 22
Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) entered into a non-binding letter of intent to acquire One Animal Hospital Located in Pennsylvania Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) entered into a non-binding letter of intent to acquire One Animal Hospital Located in Pennsylvania on September 21, 2023. The letter of intent is non-binding and subject to additional due diligence. The transaction is anticipated to close October 2023. Announcement • Sep 14
Inspire Veterinary Partners, Inc. Announces Executive Appointments Inspire Veterinary Partners, Inc. announced the addition of three veteran leaders to further strengthen its medical, operational and financial expertise in support of its future growth and development. In alignment with the company's growth plan outlined in the Initial Public Offering for Inspire, the Company welcomes: Dr. Chuck Dunn, as Director of Medical Operations; Kimberly King as Director of Field Operations; and Debbe Bastian, Finance Controller. Each of these new additions to the Inspire team will report into established department leadership in Operations, Medicine and Finance. Dr. Chuck Dunn, Director of Medical Operations is a small animal veterinarian with more than 27 years of clinical practice experience and multi-site leadership. He has a B.S. in Animal Science from the University of Florida and a V.M.D. from the University of Pennsylvania. In addition to his medical and surgical experience, he has held regional and national medical leadership positions in large-scale, multi-unit veterinary practices and industry-leading veterinary pharmaceutical companies such as Mars Veterinary Health and Zoetis Animal Health. Kimberly King, Director of Field Operations, comes to Inspirewith more than 20 years of experience in the healthcare field including 16 years in veterinary medical operations, working with large multi-unit organizations including Mars Veterinary Health. She serves as the operations and business field lead for Inspire and brings the ability to optimize operational efficiency, facilitate effective communication and balance location autonomy and has a demonstrated track record of opening and growing locations in year over year performance. Debbe Bastian, Finance Controller has served for over 30 years as a licensed CPA, Chief Financial Officer and Financial Analyst for firms in a wide variety of sectors including software, real estate, staffing and manufacturing. She has presided over financial workflows for private and public entities and has experience in M&A work, operational finance and SEC reporting. At Inspire she is responsible for the company's day-to-day financial functions, including accounting, financial reporting, systems implementation and corporate finance. Ms. Bastian holds a BBA in Accounting from West Texas A&M University. Reported Earnings • Sep 04
Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.13 loss in 2Q 2022) Second quarter 2023 results: US$0.23 loss per share (further deteriorated from US$0.13 loss in 2Q 2022). Revenue: US$4.49m (up 94% from 2Q 2022). Net loss: US$1.23m (loss widened 90% from 2Q 2022). Announcement • Sep 03
Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) entered into a non-binding letter of intent to acquire a 100% ownership interest in Two animal hospitals in new state, Oregon. Inspire Veterinary Partners, Inc. (NasdaqCM:IVP) entered into a non-binding letter of intent to acquire a 100% ownership interest in Two animal hospitals in new state, Oregon on September 1, 2023. Inspire expects to acquire real estate associated with the purchases. Transaction is subject to customary closing conditions, additional diligence, definitive agreement and other factors. Transaction is currently expected to be completed as early as the third quarter of 2023. Announcement • Aug 31
Inspire Veterinary Partners, Inc. has completed an IPO in the amount of $6.4 million. Inspire Veterinary Partners, Inc. has completed an IPO in the amount of $6.4 million.
Security Name: Class A Common Stock
Security Type: Common Stock
Securities Offered: 1,600,000
Price\Range: $4
Discount Per Security: $0.32 Board Change • Aug 30
No independent directors There are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. No independent directors (7 non-independent directors). Secretary & Director Richard Marten is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. 
